Tumor growth ratio (day 25 tumor volume vs. day 10 tumor volume) analysis further showed a significant reduction of tumor progression in both the rAd.sT.GM + anti-CTLA-4 group, and the triple treatment group compared with the control group (Figure 4B). Here, CTLA4 is linked to neoplasm.